Opinion|Videos|January 19, 2026
Additional SUMMIT Data for Bezuclastinib in Non-Advanced Systemic Mastocytosis
Author(s)Lindsay Rein, MD, Frederick Lansigan, MD
Lindsay Rein, MD, and Frederick Lansigan, MD, discuss additional findings from the SUMMIT trial from ASH 2025 for bezuclastinib in non-advanced systemic mastocytosis.
Advertisement
Episodes in this series
Lindsay Rein, MD, and Frederick Lansigan, MD, discuss additional SUMMIT trial data presented at ASH 2025, expanding on the clinical activity of bezuclastinib (CGT9486) in non-advanced systemic mastocytosis. They examine durability of response, patient-reported outcomes, and longer-term safety observations. Rein and Lansigan consider how these results further clarify the potential role of bezuclastinib in disease management.
Advertisement
Related to this article
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.
Bringing some or all clinical trial-related activities directly to patients can help overcome barriers that prevent many people from participating.
Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.
Alpha DaRT plus pembrolizumab produced responses in all evaluable elderly patients with PD-L1–positive recurrent/metastatic head and neck cancer.
High CR/CRi rates were shown for olverembatinib plus blinatumomab in relapsed/refractory Ph-positive chronic myeloid leukemia and B-ALL.
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
4
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
5